DeciBio Analytics Launches DxBooks Databases
DeciBio Analytics, the market intelligence subsidiary of DeciBio Consulting, has launched the 2021 edition of the DxBooks. These clinical diagnostic databases include the Infectious Disease DxBook, the Oncology DxBook, and the SARS-CoV-2 DxBook. Formerly known as the Emmes Databases, the DxBooks cover molecular diagnostic testing practices at over one thousand hospital, reference, and public health labs in the U.S.
Each database provides detailed quantitative and qualitative information about labs’ diagnostic testing practices, including test adoption, kits and platforms utilized, testing volumes, trends, and more. DxBooks’ web-based Tableau interfaces complement the raw data sets by intuitively facilitating point-and-click data slicing and quick insights.
The flagship Infectious Disease DxBook covers 31 assays (both single-analyte and multi-plex panels) in 1,000 U.S. labs, beginning as early as 2016. The Oncology DxBook covers 26 oncology biomarkers across 300 institutions, beginning as early as 2017. Finally, the SARS-CoV-2 DxBook, newly launched in 2020, covers SARS-CoV-2 diagnostic and serology testing practices and forecasts, based on semi-annual interviews with 400 U.S. labs.
Recommended AI News: uCloudlink Expands Footprint in Southeast Asia with Local Business Partners
“These databases remain a valuable tool for our subscriber clients as well as for DeciBio’s bespoke strategic consulting practice. We’ve seen clients make great use of this data for sales and marketing, portfolio prioritization, product development, and other uses across the diagnostics space,” says David Cavanaugh, co-founder of DeciBio Consulting.
“This simultaneous rebrand and re-launch maintains the same level of high-quality data collection that our clients have relied on for years, while bringing the product identity fully into the DeciBio suite,” notes Julia Daniel, product manager for the DxBooks.
The DxBooks databases are available off-the-shelf on an annual subscription basis or as part of DeciBio Consulting’s custom strategic consulting projects.